Gilead price target lowered to $120 from $122 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm's price target on Gilead to $120 from $122 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June rel